Amlexanox peptide is also known as:
- Aphthasol
- 7-Amino-6-benzyloxy-4-hydroxy-3-chloro-chromeno[2,3-b]pyridine-5-carboxylic acid
- 5-Carboxy-7-[(E)-(3-hydroxyphenyl)methylidene]-4-hydroxy-3-chloro-1,2-chromene
- (7E)-7-Benzyloxy-4-hydroxy-3-chloro-5-[(E)-3-hydroxybenzylidene]-1,2-chromene-1-carboxylic acid
- 5-Carboxy-7-[(E)-3-hydroxybenzylidene]-4-hydroxy-3-chloro-1,2-chromene
Amlexanox peptide is a synthetic chromeno[2,3-b]pyridine-5-one derivative with anti-inflammatory and antiallergic properties. It is currently marketed as a topical paste under the brand name Aphthasol for the treatment of recurrent aphthous ulcers (RAUs), also known as canker sores. Amlexanox peptide is also being investigated for the treatment of a variety of other conditions, including inflammatory bowel disease (IBD), psoriasis, and cancer.
History of amlexanox peptide
Amlexanox peptide was first developed in the 1970s by the Japanese pharmaceutical company Otsuka Pharmaceutical Co., Ltd. It was approved by the Japanese Ministry of Health, Labour and Welfare in 1980 and by the United States Food and Drug Administration (FDA) in 1995.
Mechanism of action of amlexanox peptide
Amlexanox peptide works by inhibiting the production of leukotrienes, which are chemicals that are involved in the inflammatory process. Leukotrienes can cause inflammation by increasing blood vessel permeability and attracting inflammatory cells to the site of inflammation. By inhibiting the production of leukotrienes, amlexanox peptide can help to reduce inflammation and relieve symptoms associated with inflammatory conditions.
Clinical applications of amlexanox peptide
Amlexanox peptide is currently marketed as a topical paste under the brand name Aphthasol for the treatment of recurrent aphthous ulcers (RAUs), also known as canker sores. RAUs are small, painful sores that can develop in the mouth or throat. They are not contagious, but they can be very uncomfortable. Amlexanox peptide works by reducing the inflammation and pain associated with RAUs, and it can help to speed up the healing process.
Amlexanox peptide is also being investigated for the treatment of a variety of other conditions, including:
- Inflammatory bowel disease (IBD): IBD is a chronic inflammatory condition of the intestines. Amlexanox peptide is being investigated for the treatment of IBD because it has anti-inflammatory effects. Clinical trials have shown that amlexanox peptide can reduce inflammation and improve symptoms in people with IBD.
- Psoriasis: Psoriasis is a chronic autoimmune disease that causes the skin cells to grow too quickly. This can lead to the formation of thick, scaly patches on the skin. Amlexanox peptide is being investigated for the treatment of psoriasis because it has anti-inflammatory and immunomodulatory effects. Clinical trials have shown that amlexanox peptide can be effective in reducing the severity of psoriasis plaques.
- Cancer: Amlexanox peptide is also being investigated for the treatment of cancer because it has anti-tumor effects. Laboratory studies have shown that amlexanox peptide can inhibit the growth and proliferation of cancer cells in some types of cancer, including breast cancer, colon cancer, and prostate cancer.
Amlexanox peptide is a promising new drug with a wide range of potential therapeutic applications. It is currently marketed as a topical paste for the treatment of canker sores, but it is also being investigated for the treatment of a variety of other conditions, including IBD, psoriasis, and cancer. Future research is likely to lead to the development of new formulations of amlexanox peptide for different delivery routes and indications, as well as the confirmation of the safety and efficacy of amlexanox peptide for the treatment of a wider range of conditions.
